- Home
- ZAPP vs THAR Comparison
ZAPP vs THAR Comparison
Compare ZAPP & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZAPP
- THAR
- Stock Information
- Founded
- ZAPP 2017
- THAR 2017
- Country
- ZAPP Thailand
- THAR United States
- Employees
- ZAPP N/A
- THAR N/A
- Industry
- ZAPP Motor Vehicles
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- ZAPP Consumer Discretionary
- THAR Health Care
- Exchange
- ZAPP Nasdaq
- THAR Nasdaq
- Market Cap
- ZAPP 4.6M
- THAR 4.0M
- IPO Year
- ZAPP N/A
- THAR 2022
- Fundamental
- Price
- ZAPP $0.80
- THAR $1.90
- Analyst Decision
- ZAPP
- THAR Strong Buy
- Analyst Count
- ZAPP 0
- THAR 1
- Target Price
- ZAPP N/A
- THAR $17.00
- AVG Volume (30 Days)
- ZAPP 1.7M
- THAR 20.9K
- Earning Date
- ZAPP 01-31-2025
- THAR 11-07-2024
- Dividend Yield
- ZAPP N/A
- THAR N/A
- EPS Growth
- ZAPP N/A
- THAR N/A
- EPS
- ZAPP N/A
- THAR N/A
- Revenue
- ZAPP $17,440.00
- THAR N/A
- Revenue This Year
- ZAPP $148,455.05
- THAR N/A
- Revenue Next Year
- ZAPP $544.47
- THAR N/A
- P/E Ratio
- ZAPP N/A
- THAR N/A
- Revenue Growth
- ZAPP N/A
- THAR N/A
- 52 Week Low
- ZAPP $0.70
- THAR $1.84
- 52 Week High
- ZAPP $19.10
- THAR $7.46
- Technical
- Relative Strength Index (RSI)
- ZAPP 37.29
- THAR 43.41
- Support Level
- ZAPP $0.74
- THAR $1.86
- Resistance Level
- ZAPP $0.95
- THAR $1.95
- Average True Range (ATR)
- ZAPP 0.10
- THAR 0.07
- MACD
- ZAPP 0.01
- THAR -0.00
- Stochastic Oscillator
- ZAPP 15.56
- THAR 16.33
About ZAPP Zapp Electric Vehicles Group Limited
Zapp Electric Vehicles Group Ltd designs manufactures, and sells high-performance electric vehicles, including maintenance and repair of electric vehicles and related parts and accessories.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.